HOME > ARCHIVE

ARCHIVE

Nippon Shinyaku Licenses Leukemia Drug from CTI Technologies of US

January 6, 2003
Headquarters for Drug, Medical Device Policy Holds 1st Meeting

January 6, 2003
Pharmacia, Yamanouchi File NDA for Celecoxib

January 6, 2003
REGULATORY NEWS IN BRIEF

January 6, 2003
Kyorin, Bayer Yakuhin to Comarket Baynas

January 6, 2003
BULLETIN

January 6, 2003
Kaken to Co-promote Zyloric of GSK

January 6, 2003
The 23rd General Meeting of the Japanese Society of Clinical Pharmacology and Therapeutics (1)

January 6, 2003
BUSINESS NEWS IN BRIEF

January 6, 2003
MEDICAL DEVICE NEWS IN BRIEF

January 6, 2003
WEBSITE NEWS

January 6, 2003
OTC NEWS IN BRIEF

January 6, 2003
NEW PRODUCTS IN BRIEF

January 6, 2003
DIAGNOSTIC NEWS IN BRIEF

January 6, 2003
Medical Fees Should Be Classified into Doctors', Hospitals' Fees: Korosho's Tentative Reform Plans

January 6, 2003
January 6, 2003
Approval of 4 Drugs, Including Calblock Recommended by CDFS Panel

January 6, 2003
New Year's Greeting

January 6, 2003
Strong Incentives Essential to Development of Innovative Drugs: CEFP

December 23, 2002
RESEARCH & DEVELOPMENT NEWS IN BRIEF

December 23, 2002

ページ

Chuikyo Debate on FY2026 Drug Pricing Reform

Chuikyo OKs New CEA Handling, with Third-Party Verification Ahead

Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…

COMMENTARY

Shift Underway in Pharma Workforce as Sales Roles Shrink, Manufacturing Rises

By Hayate Horiguchi

Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…

COLUMN

The Patient North Star: How Gilead Japan Redefined Innovation

By Philip Carrigan

In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…